A clinical-stage biopharmaceutical company advancing novel therapies for central nervous system disorders including pain and inflammation while maintaining a substantial cash reserve for R&D.
Investors may consider Oric for high-risk exposure to a breakthrough therapy in the lucrative chronic pain market with a differentiated drug mechanism. The company has successfully secured substantial capital through equity financing, currently holding $45.7 million in cash and equivalents to support ongoing development efforts. If any of its clinical candidates receive approval, the potential for significant revenue growth could lead to substantial shareholder value creation.
The stock carries extreme risk given the company has generated zero revenue over the past five years while accumulating a retained earnings deficit of $692.2 million. Cash flow from operations remains deeply negative at -$111.0 million, and the widening annual losses suggest an unsustainable burn rate without imminent commercial success. The total liabilities exceed $24.5 million against limited assets, creating leverage risk if funding markets tighten or share prices decline.
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders, specifically targeting pain and inflammation. The company operates in the global pharmaceutical industry with a pipeline aimed at addressing unmet medical needs in chronic pain management. Currently, the firm relies heavily on strategic financing to fund its extensive research and development activities as it advances its proprietary drug candidates through clinical trials.
Recent financial performance indicates an intensifying cash burn rate, with net losses reaching $129.5 million in the latest fiscal year compared to $89.1 million four years prior. Despite significant capital raised through share issuances of $244.4 million and financing cash flows of $245.3 million, operating expenses climbed to $143.0 million driven by general and administrative costs of $33.2 million and other operating expenses of $109.8 million. The company's ability to extend its runway depends on successful clinical trial readouts and securing additional funding sources as the cash balance decreased by $13.7 million year-over-year.
The global pharmaceutical industry for central nervous system disorders is highly competitive with significant barriers to entry related to clinical trial costs and regulatory approval timelines. Companies in this space typically experience long development cycles of 10-15 years before generating commercial revenue, requiring substantial upfront capital investment. Market consolidation is common as only well-funded biotech firms can sustain the high failure rates inherent in drug discovery and development.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $91.8M | $110.8M | $142.9M | $143.0M |
| Operating Income | $-91.8M | $-110.8M | $-142.9M | $-143.0M |
| G&A | $25.1M | $25.6M | $28.8M | $33.2M |
| Stock-Based Comp | $14.5M | $15.2M | $20.2M | $25.0M |
| Depreciation | $966.0K | $1.0M | $1.1M | $1.2M |
| Other OpEx | $66.7M | $85.2M | $114.1M | $109.8M |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $-91.8M | $-110.8M | $-142.9M | $-143.0M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-91.8M | $-110.8M | $-142.9M | $-143.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-89.1M | $-100.7M | $-127.8M | $-129.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-89.1M | $-100.7M | $-127.8M | $-129.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $210.5M | $212.6M | $262.2M | $288.5M |
| Cash & Equivalents | $66.8M | $23.4M | $59.4M | $45.7M |
| Prepaid Expenses | $4.2M | $4.4M | $6.3M | $7.0M |
| Other Current Assets | $139.4M | $184.8M | $196.6M | $235.8M |
| Long-Term Assets | $36.7M | $39.4M | $11.9M | $120.4M |
| PP&E (Net) | $3.3M | $2.9M | $2.9M | $2.4M |
| Operating Leases | $11.0M | $9.1M | $8.4M | $6.7M |
| Other LT Assets | $22.5M | $27.4M | $588.0K | $111.4M |
| Total Assets | $247.2M | $252.0M | $274.1M | $408.9M |
| Current Liabilities | $15.4M | $20.5M | $24.8M | $20.4M |
| Accounts Payable | $1.3M | $944.0K | $1.5M | $3.8M |
| Current Leases | $2.7M | $2.8M | $3.2M | $3.3M |
| Other Current Liab | $-2.7M | $-2.8M | $-3.2M | $-3.3M |
| Long-Term Liabilities | $9.4M | $7.5M | $6.2M | $4.1M |
| LT Operating Leases | $9.4M | $7.5M | $6.2M | $4.1M |
| Other LT Liab | $39.0K | $0 | $0 | $0 |
| Total Liabilities | $24.8M | $27.9M | $31.0M | $24.5M |
| Shareholders' Equity | $222.4M | $224.1M | $243.1M | $384.4M |
| Retained Earnings | $-334.2M | $-434.9M | $-562.8M | $-692.2M |
| AOCI | $-1.3M | $258.0K | $379.0K | $786.0K |
| Total L&E | $247.2M | $252.0M | $274.1M | $408.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-89.1M | $-100.7M | $-127.8M | $-129.5M |
| Non-Cash Adjustments | $16.5M | $13.4M | $13.5M | $27.5M |
| Working Capital Changes | $-2.5M | $1.7M | $1.7M | $-9.0M |
| Cash from Operations | $-75.1M | $-85.7M | $-112.7M | $-111.0M |
| Capital Expenditures | $2.1M | $849.0K | $1.2M | $712.0K |
| Cash from Investing | $-109.2M | $-43.4M | $22.1M | $-148.0M |
| Cash from Financing | $25.2M | $85.7M | $126.5M | $245.3M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-159.2M | $-43.4M | $36.0M | $-13.7M |
| Beginning Cash | $226.5M | $67.3M | $23.9M | $59.9M |
| Ending Cash | $67.3M | $23.9M | $59.9M | $46.2M |
The company's operations are centered primarily on its core therapeutic development platform focused on the central nervous system. Revenue generation is currently driven by non-operating activities such as common share issuances and marketable security proceeds rather than product sales, reflecting its clinical-stage status. All financial activity relates to research, development, and administrative functions necessary to advance drug candidates through regulatory pathways.
The company faces substantial financial risk due to continuous net losses exceeding $120 million annually with no current product revenue stream. Heavy reliance on equity financing, evidenced by recent common share issuances of $244.4 million, indicates potential shareholder dilution if cash reserves are depleted. There is significant regulatory and clinical trial risk as the company has not yet demonstrated successful product approval or commercial viability. The operating loss trend shows widening deficits from -$89.1M in 2022 to -$129.5M in 2025, raising concerns about cash burn sustainability.
Oric possesses a proprietary intellectual property portfolio targeting specific mechanisms in pain and inflammation that differentiates it from competitors. The company maintains a strong balance sheet with over $45 million in cash and equivalents, providing flexibility to fund long-term R&D without immediate pressure for profitability. Its focus on the high-value central nervous system market offers significant potential upside if any drug candidates successfully navigate clinical trials.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.